UNSPSC 51262404: Labetalol

This classification denotes an adrenergic antagonist with the molecular formula C19H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5H8897N95, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but generally known as labetalol, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08382MIG.

UNSPSC 51262404 Labetalol is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged to this code show minimal alignment with its nominal scope. Seminole County, Florida's IFB 60459723LAS solicits naloxone and drug deactivation systems — not labetalol — on an annual basis with quarterly deliveries, while the Texas Health and Human Services Commission's RFI HHS0017013 addresses direct-to-manufacturer prescription programs at the state level without naming specific drugs. The labetalol code itself does not appear to drive active procurement activity in the recent opportunities block, and the tagged opportunities diverge substantially from the pharmaceutical antihypertensive agent the code nominally describes.

State and local issuing bodies using codes in this pharmaceutical family appear to include county health departments and state health agencies, though the recent sample is too narrow to characterize issuing-body concentration. Activity is visible in Florida and Texas, but the source does not support a broader geographic or sectoral characterization. Practitioners evaluating labetalol procurement under this code should recognize that state and local health agencies may tag pharmaceutical acquisitions inconsistently, and formal opportunities may appear under alternative codes or under broader pharmacy benefit or medical supply requisitions rather than under granular drug-specific commodity codes.